Home Care

• Should Your Patient Be Tested
• Your Newly Diagnosed Patient
• Managing Your AAT Deficient Patient

Alpha1Health.com Survey

Take our survey to help us best meet the needs of the Alpha-1 community.

 

ARALAST is available through nationwide homecare services for patient convenience.

It's easy to start patients on ARALAST. Baxter has selected three of the nation’s leading specialty pharmacies to dispense ARALAST to your patients. They are:

Accredo Therapeutics

1-866-6ALPHA1 (866-625-7421)
www.accredotx.com

Caremark Inc.

1-800-237-2767
www.caremark.com

Coram Healthcare

1-866-FOR-A1PI (866-367-2174)
www.coramhc.com

Comprehensive in-home care

• Patients are cared for by a team of highly qualified, experienced pharmacists, nurses, and client representatives

Education and nursing support

• Professional resources for all therapy options, from self infusion to nurse administered
• Convenience within the patient's home or workplace

Advocacy programs

• Case managers work with patients to advocate for access to benefits and to identify and secure appropriate reimbursment levels
• Provide information on insurance issues and state programs

Nurse-to-physician information

• Regular communication with physician ensures quality patient care

Nationwide service

• Comprehensive service whenever patients need therapy

ARALAST is also available in hospital/infusion suites for Medicare recipients.

If you or your patients have questions about accessing therapy with ARALAST, call 1-866-ARALAST (272-5278).

These links are provided for your convenience. However, they lead to external websites not created, managed, or maintained by Baxter. Baxter is not responsible for, and does not necessarily endorse, the opinions or products represented on these external pages.

ARALAST [Alpha₁-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A₁-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A₁-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information